{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.29","value":"4.63"},{"groupId":"OG001","spread":"1.22","value":"1.21"}]}],"title":"While at Rest"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.80","value":"5.00"},{"groupId":"OG001","spread":"2.46","value":"1.64"}]}],"title":"With a Swallow"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.44","value":"4.25"},{"groupId":"OG001","spread":"2.80","value":"1.79"}]}],"title":"With a Cough"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Assessment of subjective pain scores on the visual analog scale of pain intensity averaged over a week at rest, with a swallow, and with a cough. The subjects rated their pain from 0-10 on the pain intensity scale. Scores are reported as means of the pain score with standard deviation.\n\nThis outcome is reported scores collected at the post-surgery visit; 9 to 29 days after the start of study treatment.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received celecoxib PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.\n\nCelecoxib: Given PO or via feeding tube\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Celecoxib Arm"},{"description":"Patients received placebo PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.\n\nPlacebo: Given PO or via feeding tube\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Placebo Arm"}],"paramType":"MEAN","populationDescription":"One participant on the Celecoxib Arm withdrew consent from the study treatment before the Post-Operation visit and was not evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 29 days from the start of study treatment","title":"Assessment of Overall Pain Control and Management for Patients on Celecoxib Compared to Placebo - Visual Analog Scale.","type":"SECONDARY","unitOfMeasure":"score on the pain intensity scale"}